SUMMARY The efficacy and safety of cyclosporin for patients with rheumatoid arthritis (RA) were assessed in a six month double blind, placebo controlled, multicentre study. The initial dosage of the drug was 10 mg/kg daily for two months. There were many discontinuations in both the cyclosporin group (eight out of 17) and the placebo group (six out of 19). Of the patients who completed the six months of therapy, those who had received cyclosporin showed a significant improvement in the number of swollen joints, the Ritchie articular index, and pain at active movement and at rest, compared not only with their condition at the start of the study, but also with the end results of the placebo group. Major adverse reactions to the drug were gastrointestinal disturbances and nephrotoxicity, which were probably due to the relatively high dosages of cyclosporin given in combination with non-steroidal anti-inflammatory drugs.
sible, studies on experimental arthritis in rats suggest a long lasting effect of this drug.8
These findings and the favourable results of cyclosporin treatment of other autoimmune diseases in man9 it) led us to perform a double blind, placebo controlled, multicentre study to evaluate the efficacy and safety of this drug in patients with refractory RA.
Patients and methods
Patients with active and erosive definite or classical RA, according to the American Rheumatism Association criteria, and who had previously been treated with antimalarials and gold salts or Dpenicillamine were included in the study. Further The Wilcoxon two sample test was used for statistical analysis of the data for comparison of the two groups, and the signed rank test was applied for analysis within the groups.
Results
Thirty six patients (28 women and eight men, mean age 54-9 years, SD 11-2, range 24-69 years) were admitted to the study. The cyclosporin group comprised 17 patients and the placebo group 19; the demographic characteristics of the patients, which are shown in Table 1 , indicate an equal distribution over the groups. During the trial the frequency of side effects was considerable in both groups ( Table  2 ). The cyclosporin group showed a highly significant (p<0-005) rise of the serum creatinine level relative to the pretreatment values, the mean values for the group being 98-7 (SD 31-4) and 72-6 (SD 18-2) ,umol/l, respectively; in two patients the rise of the serum creatinine level was judged unacceptable for continuation of cyclosporin administration (Table 3) . Other reasons for withdrawing the drug in the cyclosporin group were gastrointestinal intolerance in four patients and absence of effect, hyperkalaemia, and lack of compliance, each in one patient (Table 3 ). In the placebo group administration was stopped in five patients because of lack of effect and in one patient who developed a duodenal ulcer ( Table 3 ).
The findings concerning clinical, laboratory, and radiological efficacy parameters for the two groups are given in Table 4 . Statistical analysis disclosed that at the start of the study the groups were comparable for each of the efficacy parameters. Further analysis was restricted to the patients who completed the six months of therapy. Comparison of the changes in both groups during the study showed significant improvement for the cyclosporin group with respect to the number of swollen joints, the Ritchie index, and pain on active movement, and pain at rest showed borderline significance ( Table  4 ). The changes in efficacy parameters within the groups over the same period are also shown in Table  4 .
As these data indicate, in the placebo group no improvement occurred in any of the parameters and the ESR was significantly higher at six months than at the start of the study. The cyclosporin group showed a non-significant decrease of the sedimentation rate (from 65 mm to 50 mm after one hour), significant improvement in the number of swollen joints, Ritchie index, and pain at both active movement and rest at six months and also less radiological progression of joint destruction, but this last was not significant relative to the placebo group.
The other parameters of efficacy and safety are given in Table 5 . At the end of the study period the values for grip strength did not differ either between or within the groups. The mean score for global 
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efficacy was significantly higher for the cyclosporin group than for the placebo group at six months, as assessed by the investigator. Moreover, the score for the cyclosporin group as assessed by the investigator was significantly higher at the end of the study than at the beginning, but was the same at both time points for the placebo group. At the end of the study the score for overall efficacy as assessed by the investigator was significantly higher for the cyclosporin than the placebo group. Mean values for haemoglobin, alkaline phosphatase, ALAT, and potassium did not change during the study either between or within the groups.
The mean value for the cyclosporin blood levels of all 17 patients treated with cyclosporin was 675 (SD 223) ng/ml.
Discussion
The main conclusion drawn from the results of this placebo controlled, double blind study is that cyclosporin improves clinically manifest symptoms, i.e., the number of swollen joints, Ritchie articular index, and pain at active movement and at rest, in patients suffering from active rheumatoid arthritis. No significant improvement in morning stiffness or laboratory parameters was found, and the placebo group showed a significant rise of the ESR. This six month study did not yield any evidence that cyclosporin can retard radiographic signs of deterioration. Reduction of radiographic progression of joint destruction, however, is by no means an effect of all 'remittive agents' or disease modifying drugs, and the only available evidence that both gold and cyclophosphamide can retard radiographic deterioration is circumstantial. 14 Cyclosporin may even retain its activity after the inductive phase of the immune response in the clinical situation since it is conceivable that in rheumatoid arthritis sensitisation has already occurred.
The number of withdrawals from the study was high in both groups, but the total of five in the placebo group because of inefficacy suggests that the basis chosen for the selection of patients was good. The improvement of symptoms in the patients with active rheumatoid arthritis treated with relatively high dosages of cyclosporin should, however, be considered in the light of the adverse reactions, i.e., gastrointestinal disturbances and raised serum creatinine levels. This rise in serum creatinine proved partially irreversible (unpublished data), which is not the case for cyclosporin nephrotoxicity in renal allograft recipients.f 6 It seems probable that the gastrointestinal and nephrotoxic reactions in our patients can be at least partially ascribed to the relatively high dosages of cyclosporin (10 mg/kg as starting dose), which are reflected in the relatively high mean trough blood cyclosporin concentrations. At present it is advised that blood levels higher than 600-800 ,ug/ml should be avoided for cyclosporin treated patients with an autoimmune disease. 17 Moreover, the concomitant treatment with NSAIDs might have led to gastrointestinal disturbances and nephrotoxicity. Besides nephrotoxicity due to NSAIDs, 18 the kidney in rheumatoid arthritis patients can be directly involved owing to the disease.19 An increased incidence of disturbances of the upper gastrointestinal tract in rheumatoid arthritis patients has been reported, but it is not clear whether this is related to the drug treatment or represents a systemic manifestation of the disease.2t
In summary, cyclosporin proved to be more effective than placebo during a six month treatment period in patients with rheumatoid athritis refractory to more conventional drugs. The observed adverse affects may have been dose related and enhanced by concomitant therapy with NSAIDs. Thus cyclosporin seems to be an effective disease modifying drug in rheumatoid arthritis, provided it is given in a daily dose not exceeding 5 mg/kg and is well monitored, with blood trough levels not exceeding 500 ng/ml. Moreover, to avoid nephrotoxicity we recommend the omission of concomitant administration of NSAIDs with the possible exception of sulindac, which is claimed to give less renal dysfunction.21
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